Merck’s Enlicitide Decanoate Achieves Key Breakthrough in Cholesterol Trials

Merck’s experimental drug Enlicitide Decanoate has achieved significant success in two late-stage clinical trials, the company announced on June 9, 2025. The trials demonstrated the drug’s ability to substantially lower LDL-C levels, commonly referred to as bad cholesterol, in patients with hyperlipidemia, a condition involving high-fat buildup in blood vessels.

The drug was tested in individuals with a history of, or high risk for, heart disease. Results confirmed meaningful reductions in LDL-C levels, making Enlicitide Decanoate a promising candidate for managing cholesterol-related health risks.

Hyperlipidemia is a key driver of cardiovascular disease globally, and Merck’s breakthrough has the potential to transform treatment strategies for millions of at-risk patients.